CN110809627A - 用于xla基因疗法的优化的慢病毒载体 - Google Patents
用于xla基因疗法的优化的慢病毒载体 Download PDFInfo
- Publication number
- CN110809627A CN110809627A CN201880043435.0A CN201880043435A CN110809627A CN 110809627 A CN110809627 A CN 110809627A CN 201880043435 A CN201880043435 A CN 201880043435A CN 110809627 A CN110809627 A CN 110809627A
- Authority
- CN
- China
- Prior art keywords
- seq
- btk
- cell
- cells
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/13—B-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/10—Protein-tyrosine kinases (2.7.10)
- C12Y207/10002—Non-specific protein-tyrosine kinase (2.7.10.2), i.e. spleen tyrosine kinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/46—Vector systems having a special element relevant for transcription elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Developmental Biology & Embryology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762488523P | 2017-04-21 | 2017-04-21 | |
| US62/488,523 | 2017-04-21 | ||
| PCT/US2018/028331 WO2018195297A1 (en) | 2017-04-21 | 2018-04-19 | Optimized lentiviral vector for xla gene therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110809627A true CN110809627A (zh) | 2020-02-18 |
Family
ID=63856377
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880043435.0A Pending CN110809627A (zh) | 2017-04-21 | 2018-04-19 | 用于xla基因疗法的优化的慢病毒载体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20200325458A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3612238A4 (cg-RX-API-DMAC10.html) |
| JP (2) | JP7471821B2 (cg-RX-API-DMAC10.html) |
| CN (1) | CN110809627A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2018256412B2 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2018195297A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12492411B2 (en) | 2018-05-30 | 2025-12-09 | The Regents Of The University Of California | Gene editing of monogenic disorders in human hematopoietic stem cells—correction of X-linked agammaglobulinemia (XLA) |
| JP7470119B2 (ja) | 2018-08-24 | 2024-04-17 | シーエスエル ベーリング ジーン セラピー インコーポレイテッド | 無血清培地におけるベクター産生 |
| US11464872B2 (en) | 2020-12-07 | 2022-10-11 | Noga Therapeutics Ltd. | Lentiviral vectors for therapeutic expression of BTK in haematopoietic cells |
| WO2025215591A1 (en) | 2024-04-12 | 2025-10-16 | Csl Behring L.L.C. | Modified vectors for xla gene therapy |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6974667B2 (en) * | 2000-06-14 | 2005-12-13 | Gene Logic, Inc. | Gene expression profiles in liver cancer |
| US20160004814A1 (en) * | 2012-09-05 | 2016-01-07 | University Of Washington Through Its Center For Commercialization | Methods and compositions related to regulation of nucleic acids |
-
2018
- 2018-04-19 AU AU2018256412A patent/AU2018256412B2/en active Active
- 2018-04-19 US US16/605,740 patent/US20200325458A1/en active Pending
- 2018-04-19 JP JP2019557373A patent/JP7471821B2/ja active Active
- 2018-04-19 WO PCT/US2018/028331 patent/WO2018195297A1/en not_active Ceased
- 2018-04-19 CN CN201880043435.0A patent/CN110809627A/zh active Pending
- 2018-04-19 EP EP18788504.1A patent/EP3612238A4/en active Pending
-
2024
- 2024-04-10 JP JP2024063151A patent/JP7696039B2/ja active Active
Non-Patent Citations (3)
| Title |
|---|
| HANNAH KERNS等: "Lentiviral Vectors Using a Ubiquitously Acting Chromatin Opening Element and Endogenous Btk Promoter Restore B and Myeloid Cell Defects in Murine X-Linked Agammaglobulinemia", 《MOLECULAR THERAPY》 * |
| HANNAH M. KERNS等: "B cell–specific lentiviral gene therapy leads to sustained B-cell functional recovery in a murine model of X-linked agammaglobulinemia", 《BLOOD》 * |
| SWATI SINGH等: "BTK-Promoter LV Vectors Utilizing Conserved Intron Element Mediate Functional Rescue in Murine XLA", 《MOLECULAR THERAPY》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024084849A (ja) | 2024-06-25 |
| AU2018256412A1 (en) | 2019-11-07 |
| WO2018195297A1 (en) | 2018-10-25 |
| EP3612238A1 (en) | 2020-02-26 |
| EP3612238A4 (en) | 2020-12-30 |
| AU2018256412B2 (en) | 2025-02-27 |
| JP7696039B2 (ja) | 2025-06-19 |
| JP2020517268A (ja) | 2020-06-18 |
| US20200325458A1 (en) | 2020-10-15 |
| JP7471821B2 (ja) | 2024-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022201307B2 (en) | Genetically modified cells, tissues, and organs for treating disease | |
| KR102907773B1 (ko) | 인간 대상체에서의 비-노화-관련 청각 손상의 치료를 위한 조성물 및 방법 | |
| AU2017315679B2 (en) | Compositions and methods for treating non-age-associated hearing impairment in a human subject | |
| KR102301464B1 (ko) | 종양 세포에 의한 면역 억제를 감소시키기 위한 방법 및 조성물 | |
| CN114176043B (zh) | 用于治疗疾病的遗传修饰的细胞、组织和器官 | |
| AU2017235661B2 (en) | Oligonucleotide probes and uses thereof | |
| KR102023584B1 (ko) | 위장관췌장 신경내분비 신생물 (GEP-NENs)의 예측 방법 | |
| CN107941681B (zh) | 鉴定生物样品中定量细胞组成的方法 | |
| KR102235603B1 (ko) | 향상된 이식유전자 발현 및 가공 | |
| ES2374954T3 (es) | Variaciones genéticas asociadas con tumores. | |
| DK2644713T3 (en) | A Method for Diagnosing Neoplasms II | |
| KR102126217B1 (ko) | 제한된 면역글로불린 중쇄 유전자좌를 가지는 인간화된 비-인간 동물 | |
| KR20220157944A (ko) | 인간 대상체에서 비-연령-연관 청각 장애를 치료하기 위한 조성물 및 방법 | |
| KR20120099363A (ko) | 탯줄 혈액으로부터의 유도 만능 줄기 세포의 생성 | |
| AU2018256412B2 (en) | Optimized lentiviral vector for XLA gene therapy | |
| KR20180117122A (ko) | 인간화 tmprss 유전자를 갖는 설치류 | |
| AU2017227596A1 (en) | Dividing of reporter proteins by DNA sequences and its application in site specific recombination | |
| AU2018204332A1 (en) | Expression cassette | |
| CA2666057C (en) | Genetic variations associated with tumors | |
| US12478665B2 (en) | Cancer vaccine compositions and methods for using same to prevent and/or treat cancer | |
| CN108239642A (zh) | 一种脂肪细胞分化相关的长非编码rna及其应用 | |
| TW202313972A (zh) | 新nrg1融合物、融合接合處及檢測彼等之方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |